Esperion Therapeutics Inc ESPR

Healthcare

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). The Company's products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company's NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD). Its NEXLETOL is an ATP Citrate Lyase (ACL), inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Its Pipeline product include Next Generation ACLYi.

NDAQ:ESPR - Post by User

Esperion Therapeutics Inc

Bullboard Posts

Post by BearDownAZon Mar 04, 2019 11:24am

109 Views

Post# 29438426

ESPR to present at ACC 2019

Esperion Announces Presentation of Bempedoic Acid Pivotal Phase 3 Study 2 Results in a Late-Breaking Clinical Trial Session at the American College of Cardiology 2019 Scientific Sessions

https://investor.esperion.com/news-releases/news-release-details/esperion-announces-presentation-bempedoic-acid-pivotal-phase-3

ANN ARBOR, Mich., March 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the results from Study 2 (1002-047, also known as CLEAR Wisdom, a pivotal Phase 3 study) of bempedoic acid will be presented in a late-breaking clinical trial session at the American College of Cardiology (ACC) Scientific Sessions & Expo in New Orleans on Monday, March 18th 2019. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are being developed as complementary, cost-effective, convenient, once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C) who need additional LDL-C lowering despite the use of currently accessible therapies. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet new drug applications have been submitted to the United States Food and Drug Administration, as well as are under regulatory review for marketing authorization by the European Medicines Agency.

Study 2 was a 52-week, randomized, double-blind, placebo-controlled study to evaluate the LDL-C lowering efficacy and the safety and tolerability of bempedoic acid 180 mg compared to placebo in 779 patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH). Topline results were previously announced in October 2018.

Details on the presentations are as follows:

Title: Efficacy and Safety of Bempedoic Acid Added to Maximally Tolerated Statin in Patients with Hypercholesterolemia and High Cardiovascular Risk: The CLEAR Wisdom Trial
Author: Anne C. Goldberg, MD, FACP, FAHA, FNLA
Date and Time: March 18, 2019 at 9:00 a.m. ET
Location: Main Tent (Great Hall), Ernest N. Morial Convention Center, New Orleans LA